Clinical Trial Detail

NCT ID NCT04152863
Title Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

melanoma

Therapies

Pembrolizumab

Coxsackievirus A21 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.